Glutazene (L-Glutamine) Dosage Recommendations
Critical Clarification: Evidence Mismatch
The provided FDA drug label evidence 1 describes flumazenil (a benzodiazepine reversal agent), NOT glutamine/Glutazene. This appears to be a database error. I will base recommendations on the available glutamine-specific guidelines and research evidence.
Recommended Dosages
For Critically Ill Adults (ICU/Parenteral Nutrition)
Parenteral glutamine should be administered at 0.2-0.3 g/kg/day (approximately 20-25 g/day for most adults) when added to parenteral nutrition in stable ICU patients 2, 3. This dosing normalizes plasma glutamine concentrations and has demonstrated mortality reduction and decreased infectious complications in meta-analyses 2.
Critical contraindication: Do NOT administer parenteral glutamine to unstable patients with liver or renal failure—this is associated with increased mortality 2.
For Pediatric Patients
Glutamine supplementation should NOT be given to infants and children up to age 2 years 4. This is a strong recommendation (Grade A) from ESPGHAN/ESPEN guidelines.
For children over 2 years with solid tumors receiving chemotherapy:
- 4 g/m²/day orally for 5 days during chemotherapy courses 5
- Maximum safe dose established: 0.65 g/kg/day 6
- The 0.75 g/kg dose caused unacceptable ammonia elevation (155 μmol/L) and should be avoided 6
For Enteral/Oral Supplementation in Adults
30 g/day orally is the therapeutic threshold for intestinal permeability reduction and clinical benefit 7, 8. Lower doses based on dietary intake (typically 5-10 g/day) have not shown efficacy 7.
Doses exceeding 30 g/day for less than 2 weeks significantly reduce intestinal permeability 8. This aligns with the daily amount of glutamine metabolized by enterocytes rather than typical dietary intake 7.
For Sickle Cell Disease
Dosing follows an escalating protocol:
- 0.1 g/kg twice daily, then 0.3 g/kg twice daily, then 0.6 g/kg once daily 9
- Pharmacokinetics show capacity-limited absorption with dose escalation
- Can be taken with or without food 9
Duration of Therapy
Most clinical trials used glutamine supplementation for less than 14 days 2. There are no long-term safety data for extended administration beyond 2 weeks in critically ill patients.
Critical Safety Warnings
Renal Toxicity Risk
A case report documents acute kidney injury from 18 g/day glutamine in an elderly patient with compromised renal function 10. The mechanism involves increased single-nephron ammonia production causing tubular toxicity. Exercise caution in elderly patients and those with pre-existing kidney disease.
Monitoring Recommendations
- Measure plasma glutamine concentrations to guide dosing when available 3
- Monitor ammonia levels in pediatric patients, especially at doses approaching 0.65 g/kg 6
- Assess renal function before initiating therapy in elderly or renally compromised patients 10
Route-Specific Considerations
Parenteral glutamine demonstrates superior efficacy compared to enteral administration 11. High-dose parenteral (>0.25-0.3 g/kg/day IV) or high-dose enteral (≥30 g/day) shows greatest clinical benefit 11.
For patients on continuous renal replacement therapy, glutamine losses approximate 1.2 g/day and may require supplementation 2.
Clinical Context Matters
The 88% of daily glutamine metabolism comes from endogenous production, with nearly half from muscle protein breakdown 7. In long-stay ICU patients, progressive muscle wasting diminishes this endogenous source, making supplementation increasingly critical 3.